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“What is the Best Way for Manufacturers and Physicians to Apply
Sunscreen to Avoid Being Burned by the Final Sunshine Act
Regulations?”
I.

INTRODUCTION

Collaboration among physicians, teaching hospitals and the life sciences industry contribute to
the design and delivery of life-saving drugs and devices, including treatments that have led to
declining death rates over the last few decades for heart disease, stroke, cancer, and HIV/AIDS.1
Approximately 83% of physicians have some type of relationship with industry.2 Such relationships
include conducting clinical trials and training physicians on how to safely use a new device.
While the overwhelming majority of these relationships are beneficial to the continued innovation
and improvement of our health care system, “some payments from manufacturers to physicians and
teaching hospitals can also introduce conflicts of interests that may influence research, education,
and clinical decision-making in ways that compromise clinical integrity and patient care, and may
lead to increased health care costs.”3 However, even the Centers for Medicare & Medicaid Services
(CMS) recognized that it has “no empirical basis for estimating the frequency of such problems, the
likelihood that transparent reporting will reduce them, or the likely resulting effects on reducing
the costs of medical care.”4
Nevertheless, several high profile cases and investigations involving unreported payments from
manufacturers to physicians, and increased regulation of such relationships among industry,
physician groups, institutions, and several states, provided the impetus for Congress to enact the
Physician Payment Sunshine Act (“Sunshine Act”), a national transparency program for the public
reporting of physicians’ financial relationships. While transparency will shed light on the nature and
extent of these relationships, and may discourage inappropriate relationships, it is unclear whether
Sunshine Act will lower health care costs or improve patient outcomes.

1
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POLICY RECOMMENDATIONS
• Applicable Manufacturers Must Begin Training Employees on the Final
Regulations and Put in Place New Policies and Procedures to Reduce Fraud
and Litigation Risks and Identify High-Risk Relationships
• Applicable Manufacturers, Researchers and Teaching Hospitals Must
Ensure Compliance with Reporting Research Payments to Avoid Violating
FDA, NIH, and Institutional Requirements That May Call Into Question the
Integrity of Research Data or Delay Research
• Officers Responsible for Attesting to Payment Reports and Employees
Engaged in Sunshine Reporting Must Exercise Due Diligence to Avoid
Potential Individual Liability

II.

BACKGROUND

A physician survey conducted in 2003 and 2004 found that pharmaceutical companies paid more
than a quarter of physicians in the preceding year for consulting, giving lectures, or enrolling
patients in clinical trials.5 In 2005, these companies spent nearly $7 billion on physician detailing
and provided free samples with a retail value of more than $18 billion.6 Researchers and faculty
at academic medical centers (AMCs), as well as accredited continuing medical education (CME)
providers also receive funding from industry.

2

Despite the enormous benefits of such collaboration, some have claimed that these relationships
may also influence physicians’ behavior in ways that undermine their independence and objectivity
in prescribing, teaching, learning and practice. For example, some studies have shown that
physician interactions with industry are associated with a greater willingness to prescribe newer,
more expensive drugs.7 There has also been concern that clinical research funded by manufacturers
is not transparent and may be more likely to reach conclusions favorable to the sponsor than nonindustry-sponsored studies.8
In response to heightened legal and public scrutiny of physician–industry relationships, industry
and physician groups, such as the American Medical Association (AMA) and the Pharmaceutical
Research and Manufacturers of America (PhRMA), developed voluntary guidelines to manage
interactions between manufacturers and physicians.9 In addition, a growing number of AMCs,
professional medical associations, medical journals, and clinical guideline-writing committees have
adopted stringent rules for interactions with the industry and several states10 have also enacted
transparency laws. Notwithstanding these developments, some have expressed concern that
industry guidelines are voluntary and States have been criticized for having payment data websites
that are unsearchable or difficult to access. Given these concerns, coupled with the growing
amount and scope of industry involvement in medical research, education, and clinical practice,
the Medicare Payment Advisory Commission (MedPAC) and the Institute of Medicine (IOM)
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recommended in 2009 that Congress enact a new regulatory program to address transparency in
physician-industry relationships.11 This led to Senators Charles Grassley and Herb Kohl to propose
the Sunshine Act, which was eventually included in Section 6002 of the Patient Protection and
Affordable Care Act (PPACA).
III.

ISSUES IN DISPUTE

Proponents of transparency laws argue that comprehensive information about physicians’ financial
relationships with manufacturers would help payers and health plans examine whether and to
what extent industry ties influence physicians’ practice patterns, such as the drugs they prescribe
and the procedures they perform. Such laws, proponents argue, would also enable patients to make
better informed decisions when choosing physicians and making treatment decisions. Such laws
might also deter physicians from participating in improper arrangements that violate industry and
professional standards, which can sometimes lead to increased healthcare costs. Public reporting
may also allow AMC’s to verify the financial interests of their clinical investigators, and help media
and researchers shed light on physician–industry interactions and identify potential conflicts of
interest.
Despite these arguments, government officials have acknowledged that support “for greater
transparency does not imply that all—or even most—of these financial ties are inappropriate or
undermine physician–patient relationships.”12 In fact, much collaboration between researchers and
the industry have benefited patients by translating research discoveries into new drugs and devices.
In addition, manufacturers’ marketing efforts may lead to increased use of beneficial drugs13 and
keep physicians informed about new safety data, such as black box warnings. Furthermore, it is
important to recognize that information may be of limited use to individual patients because they
lack the medical expertise to understand the nature of particular relationships or arrangements.

3

Moreover, a public reporting system might discourage physicians and other providers from having
legitimate research, consulting, education, and training arrangements with manufacturers that
benefit patients and pose little risk of abuse. For example, a recent survey of over 1,000 physicians
found that 66% would reduce their interactions with industry if false or incorrect information was
disclosed.14 Finally, with an estimated cost of $269 million in the first year and $180 million annually,
along with dedicating hundreds of thousands of hours and numerous employees, including training
and education, the Sunshine Act will impose significant compliance costs on manufacturers and
administrative costs on the government.
IV.

RESEARCH AND RESPONSE

The Sunshine Act requires applicable manufacturers of drugs, devices, biological, or medical
supplies covered under Medicare, Medicaid or CHIP, to report annually to CMS, in an electronic
format, certain payments or other transfers of value (“payment”) to covered recipients—physicians
and teaching hospitals. The Act also requires AMs and applicable group purchasing organizations
(GPOs) to report certain information regarding the ownership or investment interests held by
physicians or the immediate family members of physicians in such entities.15
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AMs and GPOs must begin collecting the required data on August 1, 2013 and report payment data
through December 31, 2013 to CMS by March 31, 2014. CMS then expects to publish the data for
this period on a public website by September 31, 2014. AMs and GPOs that fail to comply with the
reporting requirements may be subject to civil monetary penalties.
A.

All Stakeholders Must Determine if They Are Applicable Manufacturers Required to
Report

Applicable manufacturer (AM) is defined as an entity that “operates” in the U.S.16 and is “engaged in
the production, preparation, propagation, compounding, or conversion of a covered drug, device,
biological, or medical supply ….” The definition does not include foreign entities that contribute
to manufacturing, but have no presence in U.S.17 A covered product means that payment must be
available under Medicare, Medicaid or CHIP and the product requires a prescription or premarket
approval (devices). This includes products that are reimbursed separately or as part of a bundled
payment.18
An entity that is under “common ownership”19 with an AM and “provides assistance or support”20 to
such entity also qualifies as an AM. The definition does not cover entities that only manufacture raw
materials or components which are not covered products, unless under common ownership with
an AM and assist or support manufacturing. The definition also specifically excludes distributors,
wholesalers, repackagers, relabelers, and kit assemblers that do not hold title to any covered drug,
device, biological or medical supply. It also excludes hospitals; hospital-based pharmacies and
labs that manufacture a covered product solely for use by or within entity itself or by entity’s own
patients; pharmacies; and compounding pharmacies that meet three specified requirements.

4

CMS finalized that AMs with less than 10% of total (gross) revenues of covered products must attest
to that fact, and only have to report payments associated with those covered products. For AMs
that have a separate operating division (e.g. animal health), the division need only report payments
related to covered products if the division only produces non-covered products and does not meet
the definition of providing assistance and support.21 Finally, entities that previously did not have any
other covered product become an AM 180 days after its product becomes available for payment
by CMS or CHIP.
B.

Applicable Manufacturers Must Clearly Identify Which Transactions and Relationships
Are With Covered Recipients and What Individuals are Excluded

Covered recipients (CRs) include physicians (MD’s, DO’s, dentists, dental surgeons, podiatrists,
optometrists or chiropractors), and group practices. This includes all physicians that have a current
license, regardless of whether they are enrolled with CMS or currently seeing patients. Medical
residents are not CRs and payments to legal agents of AM that happen to have physicians on staff
are not reportable payments. Teaching hospitals are also CRs and include any hospital receiving
Medicare payments for direct graduate medical education (GME) or Indirect Medical Education
(IME) payments.22 Payments to a veterinary school associated with hospitals are excluded. CMS will
publish a list of hospitals once annually that will be available 90 days before the reporting year and
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will include tax identification numbers. While Congress must amend the Sunshine Act to include
any other CRs (e.g., nurses), States are able to require reporting for non-covered recipients without
those provisions being preempted.
CMS also clarified that payments made “at the request of” or “designated on behalf of” a CR are
different from indirect payments. If a CR directs that an AM provide payment to a specific entity or
individual, rather than receiving it personally, then such payment is being made “at the request” of
such CR, and therefore the AM must report the name of the CR, and the name of the entity paid
or “individual” (name not required). If the CR neither accepts payment nor requests it be directed,
then no reporting of the payment is required. When a CR does not receive payment, but an AM
provides payment to another entity or individual in the name of the CR, then the payment has been
“designated on behalf of” a CR, and therefore must be reported. For example, if a physician waives
his payment but the AM donates the payment to charity on behalf of the physician, such payment
must be reported. Accordingly, physicians must make clear prior to performing a specified service
or entering into a contract whether their fee will be waived or paid to another individual or entity.
An important provision for AMs to analyze is whether certain physicians are “bona fide” employees
of the AM, and thus exempt from the reporting requirements. CMS will use a case-specific analysis
to determine if: (1) board members, (2) medical directors, (3) retirees, and (4) prospective employees
are eligible for exclusion. Accordingly, when structuring employment arrangements with physicians,
AMs should reference section 3121(d)(2) of the Internal Revenue Code, which CMS used to define
“employee” in the final regulations. AMs should also consult guidance from HHS-OIG regarding
the bona fide employment exception in the Anti-Kickback Statute (AKS). Finally, AM’s should be
prepared to report payments to prospective employee physicians (e.g., recruiting costs), including
any travel, lodging, and meals.
C.

5

Applicable Manufacturers Must Use a Consistent and Transparent Methodology When
Reporting Payment Information and Choosing the Nature of Payment

AMs must report a physician’s name and business address, NPI number (individual, not group),23
specialty, state professional license number for at least one state, and the date24 of payment.
Payments made to physician group practices must be attributed only to physicians who requested
the payment; on whose behalf the payment was made; or who are intended to benefit from the
payment. For payment amount, AMs must make a reasonable, good faith effort to determine the
“discernible economic value,” even if the payment has no discernible value to the CR or the CR
does not request it. In addition, all aspects of the payment must be included when calculating,
including tax and shipping. Next, AMs must report the form of payment, which can be: (1) cash or
cash equivalent; (2) in-kind items or services; (3) stock, stock option, ownership interest; (4) dividend,
profit or other return on investment.
Separate and apart from the form of payment, AMs must report one of sixteen nature of payment
descriptions. While some are straightforward, such as travel; entertainment; gift; grant; honoraria;
royalty or license; and space rental or facility fees (for teaching hospitals only), other categories
require closer analysis. For example, CMS finalized that charitable contributions include, but are not
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limited to, any payment made to an organization with tax-exempt status, which is not provided
in exchange for any goods, items or services.25 Thus, in circumstances where a physician provides
consulting services to an AM, but requests that his payment for the services be made to a charity,
it would be reported as a consulting fee with the physician as the CR, rather than a charitable
contribution, because the physician directed the payment.
CMS also finalized that for meals in a group setting (other than buffet meals provided at conferences
or other similar large-scale settings), AMs must divide the total value of the food or beverage
provided by the number of people who actually partook in the meal, including both CRs and
non-covered recipients (such as support staff ).  If the per-person cost exceeds the minimum $10
threshold, then the AM must report the food or beverage as a payment for each CR who actually
partook in the group meal.26 AMs must also report meals that are dropped off at a CRs office (e.g.,
sales rep) and other meals where the attendees are not controlled or selected by the AM. AMs must
use the same attribution method for all meals regardless of whether the sales rep remained in the
office for the entire meal. Even if the meal is under $10, AMs must still track food and beverages
provided to CRs in case their total annual payments exceed $100.
If payment relates to marketing, education, or research of a covered product, the related covered
product must also be identified. AMs may report up to five covered products related to each
payment.27 AMs must indicate “non-covered product” for payments related to a specific noncovered product and “none” if the payment is not related to any product (covered or not).28 AMs may
also voluntarily provide up to 200 characters of contextual information about a specific transaction.
Finally, AMs may, but are not required to, file an assumptions document with their reports to explain
any assumptions made when collecting and reporting data and choosing particular nature of
payment categories. Such documents will not be made public or provided to CRs, and will likely
be protected from Freedom of Information Act requests under Exemption 4, which protects trade
secrets and commercial or financial information that is obtained from a person and is privileged or
confidential.
D.

6

Applicable Manufacturers, Researchers and Institutions Must Understand What
Payments Are Eligible for Delayed Publication

The Sunshine Act allows CMS to grant a delay in publication for payments related to: (1) research29
on, or development of, a new drug, device, biological, or medical supply, or a new application of
an existing drug, device, biological, or medical supply; or (2) clinical investigations regarding a new
drug, device, biological, or medical supply. CMS finalized, however, that payments in connection
with research related to new applications of existing products will not be subject to delayed
publication unless the research activities that resulted in the payment were not within the scope of
a “clinical investigation.”30 Payments for pre-clinical research, which includes “laboratory and animal
research that is carried out prior to beginning any studies in humans, including FDA’s defined
phases of investigation,” are also eligible for delayed publication. CMS will not delay payments for
“business development activities.”

FDLI’S   FOOD AND DRUG LAW POLICY FORUM   //   A PUBLICATION OF THE FOOD AND DRUG LAW INSTITUTE    //   www.fdli.org

For the research payment to qualify for delay, it must be subject to a written agreement31 or
contract or a research protocol. AMs wishing to have their research payments delayed still report
the payment, but indicate to CMS its eligibility for delay. CMS will not publish the payment, and
such data will not be subject to disclosure under 5 U.S.C. § 552, or any similar Federal, State, or local
law, until FDA approves, licenses, or clears the product under research or four years after the date
of payment, whichever comes first. The AM must continue to indicate such payment is eligible for
delay annually and notify CMS if the product has received FDA approval or clearance. Payments will
be made public “even if a product never received FDA approval, licensure or clearance.”
AMs must report the: (a) name of the research study; (b) name(s) of any related covered products;
and (c) identifying information about each physician investigator.32 AMs may also voluntarily submit
contextual information about the research and the ClinicalTrials.gov identifier. AMs must also report
the total amount of the research payment, including costs associated with patient care such as
diagnostics, exams, laboratory expenses, time spent by health care professionals treating the
patient and managing the study, and the provision of study drugs, devices, biologicals, and medical
supplies or other in-kind items. Finally, when reporting research payments, AMs should separately
report travel, meals, speaking, or other segregable activities, unless such payments are included in
the written agreement and paid for through the large research contract.
E.

Applicable Manufacturers and Physicians Must Be Clearly Aware of Which Payments
or Transfers of Value Are Excluded From Reporting or Tracking

CMS finalized fourteen categories of payments that are excluded from reporting. States, however,
can require reporting of categories excluded by the Sunshine Act, except for the $10 minimum.
Several exclusions are somewhat straightforward: discounts or rebates; loans of covered devices
or devices under development for up to 90 days; contractual warranties; charity care; product
samples; personal transfers of value; a physician acting as a patient (e.g., research subject); and legal
services provided by a physician. Other categories, however, such as indirect payments, require
great attention to ensure that AMs do not knowingly fail to report otherwise reportable payments.

7

CMS finalized that buffet meals, snacks or coffee provided at conferences or other similar large-scale
settings, where it would be difficult to establish the identities of the physicians who partook in the
meal or snack, are exempt from reporting. This exclusion does not apply to meals provided to select
individual attendees at a conference where the AM can establish the identity of the attendees.  Next,
CMS excluded payments provided as compensation for speaking at a continuing education (CE)
program, including prescriber education required by REMS, if three conditions are met.
First, the event at which the CR is speaking must meet the accreditation or certification requirements
of one of five entities.33 Second, the AM must not pay the CR speaker directly. Finally, the AM must
not select the CR speaker or provide the third party (e.g., CE vendor) with a distinct, identifiable set of
individuals to be considered as speakers for the CE program. AMs, however, must report payments
for speaking at an unaccredited and non-certified CE program and for speaking engagements not
related to medical education—each with their own category.
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AMs will not be responsible for reporting under the “education category” or any other nature of
payment category payments made to CE vendors that are used to subsidize attendees’ tuition fees
for CE events. However, payments or other transfers of value associated with attendance of an
event (such as travel and meals) must be reported as required. AMs are not required to report the
provision of written materials that have been approved by FDA under a REMS for distribution to
physicians, such as Dear Healthcare Provider letters, and other REMS educational materials may be
excluded if they fall are intended for patient use.
One category of excluded payments AMs must play close attention to is payments less than $10.
For practical purposes, AMs will still have to track all payments to CRs regardless of amount because
reporting is required when the total annual value of payments provided to a CR exceeds $100.34
Small incidental items under $10 (such as pens and note pads) that are provided at large-scale
conferences or events open to the public, where it would be difficult for an AM to identify physician
CRs, are exempt from the reporting requirements, including the need to track them for aggregation
purposes.
AMs must also clearly understand when to exclude payments related to educational materials that
directly benefit patients or are intended for patient use, which include an anatomical or wall model
given to a physician to help explain to patients how a procedure would work. AMs may include
overhead expenses, such as printing and time, in the exclusion as long as they are directly related
to the development of the materials. Medical textbooks, marketing and promotional materials, and
journal reprints do not fall within the exclusion.
Finally, an AM will not need to report indirect payments if the AM is unaware35 of the identity of
the CR during the reporting year and the second quarter of the subsequent year following the
indirect payment.36 In addition, if an AM requires, instructs, directs, or otherwise causes a third party
to provide a payment, in whole or in part, to a CR, such payment must be reported, regardless
of whether the AM specifies the CR. For example, if an AM provided an unrestricted donation to
a physician professional organization, and the organization uses the donation to make grants to
physicians, those grants would not constitute “indirect payments” because the AM did not require,
instruct, or direct the organization to use the donation for grants to physicians.
F.
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Applicable Manufacturers, Covered Recipients and CMS Must Work Together to
Ensure That Disputes and Corrections Are Resolved

After CMS collects and aggregates all payment reports, the agency will notify AMs and CRs that the
data is available for review.37 The online notification will inform CRs of the date their 45-day review
period begins. Physicians will then be able to sign into CMS’ website securely, review only their data,
and initiate a dispute if necessary, which gives AMs and CRs an additional 15 days to resolve the
dispute. CMS, however, will not be involved in resolving the dispute. Only data changes initiated
during the 45-day review and correction period and resolved by the end of the 15-day period will
be captured in the initial publication of the current reporting year of data on the public website. If
the dispute is not resolved in this period, CMS will publish the payment with the notation “disputed.”
For any corrections or omissions, the AM must re-submit and re-attest to the new data. After this
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period, CMS will publish the data on its website, OPENPAYMENTS. The website must be searchable,
understandable, easily aggregated and downloadable, provide background on industry-physician
relationships, and include any enforcement activities taken.
AMs may be penalized by CMS or OIG for failing to timely, accurately or completely report payments,
which includes failing to report an entire transaction or certain fields related to a transaction (e.g.,
date). Failure to report payments may be penalized $1,000 to $10,000 per payment, up to $150,000
annually. Knowing failures to report payments may be penalized $10,000 to $100,000, up to
$1,000,000 annually. In determining the amount of penalty CMS or OIG will look at: (1) the length of
time the AM failed to report; (2) the value of the payment; (3) the level of culpability; (4) the nature
and amount of information reported in error; and (5) the degree of diligence exercised in correcting
information reported in error.
Errors corrected during the 45-day review and correction and dispute resolution period will not be
subject to penalties as long as the original submission was made in good faith. Errors or omissions
outside of this period, however, are subject to penalties. Accordingly, AMs must submit corrected
information to CMS immediately upon confirmation of the error or omission. AMs must also
maintain, for at least 5 years (up to 9 years for delayed research payments), all books, contracts,
records, documents, other evidence sufficient to enable CMS or OIG to audit, evaluate and inspect
compliance with reporting requirements.
V.

IMPACT OF POLICY RECOMMENDATIONS

Compliance with the reporting requirements does not exempt AMs or CRs from any potential
liability under the AKS or the False Claims Act (FCA). However, CMS made “clear that the inclusion
of a payment … on the public database does not mean that any of the parties involved were
engaged in any wrongdoing or illegal conduct.” Moreover, the statute does not limit or ban such
payments in any ways. Nevertheless, the government will use sophisticated data analytics to detect
and prosecute health care fraud through Sunshine reporting and increased data sharing across
government agencies.
A.
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Applicable Manufacturers Must Begin Training Employees on the Final Regulations
and Put in Place New Policies and Procedures to Reduce Fraud and Litigation Risks
and Identify High-Risk Relationships

Payments to physicians for speaking, travel, meals, research, consulting, and other services may
violate the AKS if any one purpose of the payment is to induce physicians to prescribe medication
or refer patients for goods or services paid for by CMS. Under PPACA, violations of the AKS can serve
as the basis for FCA violations for all claims submitted that resulted from illegal remuneration. Public
disclosure of physician investment or ownership interests in a manufacturer will also raise issues
under the Stark Law. Moreover, AMs will also need to ensure compliance with a growing number of
international transparency laws and foreign industry guidelines.38
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To prevent or reduce the likelihood of violations under the AKS, FCA, or Stark, AMs should consider
implementing annual spending limits for physicians and establish a formal process to ensure
that all payments are fair market value. AMs should ensure that all relationships are “in response
to a legitimate need” and use a written agreement for all relationships to document such need
and to ensure there is a connection between the competence of the CR and the purpose of the
relationship, as well as a reasonable number of individuals hired to achieve the intended purpose.39
In addition, AMs should implement periodic (monthly or quarterly) transparency evaluations and
audits to monitor payments at pre-established benchmarks to avoid potentially suspect payment
amounts or trends at year-end and to focus on high-risk payment category areas (e.g, speaking).40
Companies should also consider establishing a transparency or disclosure committee, led by the
Chief Compliance Officer, which includes staff from various business components (e.g., sales, medical
affairs, education). The committee, which should report directly to the AMs Board, should monitor
company payment trends, compliance with data collection requirements and provide oversight for
the conduct of employees who engage in transactions with physicians (e.g., sales reps).41
In addition, because CMS did not specifically define what constitutes a “large-scale setting,” AMs
should establish written policies and procedures for employees to determine when tracking is not
required for meals, beverages, and small items (e.g., over 50 people). AMs must also have clear
policies for employees to determine exactly what items are educational materials and are exempt
from reporting and tracking. AMs should establish policies for employees regarding samples given
to physicians, even though they are excluded from reporting, to ensure compliance with the
Prescription Drug Marketing Act, as well as Section 6004 of PPACA. AMs must also have policies
in place for employees to determine the proper standard of “awareness” when distributing grants,
donations or other payments to third parties to ensure that any transactions qualifying as indirect
payments are reported. Similarly, AMs and third parties need written policies for employees to
determine whether meals, travel or other items of value (e.g., educational items) not directly paid
by a sponsor, must be reported as indirect payments. These policies, which could also be outlined
in an AMs assumption document, will be critical do avoid knowing violations that AMs should have
reported. Such policies must also identify which employees or departments will be responsible for
reporting which relationships or payments.
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Physicians must also be extremely careful about the related covered product that AMs must report
along with a particular transaction. Government officials may use a physician’s reported specialty
to determine if payments are being made to a physician for an off-label use (e.g., a psychiatrist
receives a payment related to an anti-epileptic drug). Accordingly, both AMs and physicians must
clearly identify which covered products a particular relationship will pertain to, and should avoid
relationships or activities with particular specialties that may suggest that the physician assisted in
some form of off-label promotion.
Teaching hospitals must also avoid violating the AKS by ensuring that Pharmacy and Therapeutics
Committees operate with a “strict conflicts of interest policy to assure that payments from industry
to individuals on the Committee or to the institution cannot in practice or perception influence
purchasing decisions.”42 Payment disclosure will also draw attention to “decisions by senior officials,
including executives, Deans and Department Chairs, [who] may influence utilization of products
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and services” as well as individuals who have a license or equity interest in a product or device
utilized by or the subject of research at the institution.43
Moreover, federal and state prosecutors will use payment data to call into question the medical
necessity of treatment provided and to analyze claims tied to physicians, “including the number of
surgeries conducted, and prescriptions for off-label use of medications or high cost drugs,” which
could lead to FCA investigations.44 In addition, collection of NPI numbers will raise concerns for
AMs because it will permit researchers to link information on providers’ financial relationships to
Medicare claims data (e.g., Part D drugs) to evaluate the impact of these interactions on prescribing
practices. However, such data may be irrelevant. For example, a recent study showed that the
transparency laws in Maine and West Virginia had a negligible to small effect on prescribing and
healthcare expenditures related to statins and SSRIs.45
Additionally, a qui tam lawyer or investigator may expose AMs to price reporting risks if they
discover suspicious payments that may be characterized as “disguised discounts” that the AM failed
to include in its report. For example, CMS or OIG may view a payment for consulting fees above
fair market value as a discount that must be taken into account for government price reporting
obligation purposes. In addition, the Sunshine Act may result in actions against AMs and physicians
under state consumer protection laws, as was the case in Oregon, where the Attorney General
recently brought an action against a physician for failing to disclose financial conflicts of interest
to patients. Oregon also brought an action against a company, under the same law, for failing to
disclose conflicts of interest when disseminating promotional material.
Finally, determining whether an AM should submit an assumptions document is problematic
because reporting based on assumptions “would be open to prosecution,” and other HHS divisions,
the Department of Justice (DOJ), or OIG could request access to the documents as part of an audit
or investigation into an AM. On the other hand, reasonable and well-thought-out assumptions
could assist in showing that any omission or improperly reported data was not the result of
deliberate ignorance or reckless disregard that could lead to increased penalties. Accordingly, AMs
must carefully weigh these concerns, and should draft such documents with an eye towards how
an OIG or DOJ investigator or attorney would interpret them.
B.
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Applicable Manufacturers and Researchers Must Ensure Compliance with Reporting
Research Payments to Avoid Violating FDA, NIH, and Institutional Requirements That
May Jeopardize or Delay Research

While CMS does not need to verify research agreements, AMs must closely analyze such agreements
to ensure compliance with the AKS and NIH and FDA regulations. For example, NIH regulations
require institutions—such as AMCs—applying for Public Health Service (PHS) grants to obtain
financial disclosure statements from investigators who plan to participate in the research and must
manage, reduce, or eliminate significant financial interests that could be affected by the research.
The institution must also report the existence of conflicting financial interests to the government
agency that awards the grant and assure the agency that the interest has been managed, reduced,
or eliminated. Thus, institutions and researchers will need to closely track when payments to a
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physician exceed $5,000—the threshold for a significant financial interest. Additionally, institutions
and researchers will need to resolve the differences between NIH and Sunshine regulations
regarding the reporting of any reimbursed or sponsored travel related to investigators’ institutional
responsibilities.46 FDA also has disclosure requirements for investigators that AMs and researchers
must ensure compliance with to avoid FDA rejecting data or research and a product application
being denied or delayed.47 Discrepancies between Sunshine Act, NIH and FDA disclosures could
lead to NIH freezing grant money for a particular researcher or entire institution, or FDA delaying
or rejecting a product application. Additionally, physicians must be aware that the new reporting
requirements may jeopardize their membership on NIH study groups, FDA advisory committees,48
professional medical associations (including senior positions, e.g. chairs), and guidelines committees.
AMs must also be careful when reporting the related covered product associated with a research
payment, particularly if the research is for a new or unapproved indication. Although such payments
are delayed publication, it is still possible for CMS to share this data with OIG or DOJ, who could begin
or enhance investigations into off-label promotion and any related false claims associated with such
payments. Additionally, such payments could call into question the sufficiency of research data or
journal articles used to support the safety and efficacy of off-label uses, causing FDA to reject a new
indication. Such payments could also raise concerns about the data and research submitted to CMS
to obtain listings in the medical compendia to establish that off-label uses are medically accepted
and thereby eligible for coverage by federal healthcare programs, as was recently alleged in the
Amgen settlement.49
C.

Officers Responsible for Attesting to Payment Reports and Employees Engaged
in Sunshine Reporting Must Exercise Due Diligence to Avoid Potential Individual
Liability
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Another area of concern, particularly for executives of AMs, is the attestation requirement. Payment
reports must include an attestation by the Chief Executive Officer, Chief Financial Officer, Chief
Compliance Officer, or other Officer of the AM that the information reported is timely, accurate, and
complete to the best of his or her knowledge and belief. Such officers must also re-attest to any
reports that require subsequent corrections. This requirement could expose such officers to liability
under the Park doctrine and aggressive prosecutors may use such certifications as a means to prove
that an individual knew or should have known of fraudulent or illegal activity.
Even more problematic, OIG may also use such certifications as evidence for both mandatory and
permissive exclusions against executives and employees responsible for reporting. For example, OIG
may take a broad interpretation of a knowing failure to report or correct a payment as a program
related crime that requires mandatory exclusion, given that CMS is implementing the Sunshine
Act, coupled with the broad definition of “related to the delivery of a healthcare item or service”
and the Act’s legislative history and purpose to protect the integrity of payments made by CMS.
Thus, an officer attesting to or an employee contributing to such inaccurate reporting could have
committed a program related crime, which could result in a mandatory exclusion under 42 U.S.C.
§ 1327a-7(a)(1).
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Alternatively, OIG may consider a violation of the reporting requirements and subsequent
certification of such inaccurate reporting as a criminal offense “relating to fraud … or other financial
misconduct,” which could result in a permissive exclusion under 1327a-7(b)(1)(B). AMs should
also be aware that subsection (b)(9) already allows permissive exclusion for any entity that fails
to disclose required information regarding ownership and (b)(11) for failure to supply payment
information. Thus, OIG may propose regulations to expand these sections to cover failures to
disclose or inaccurate payments under the Sunshine regulations.
OIG may also permissively exclude any individual “who has a direct or indirect ownership or control
interest in a sanctioned entity50 and who knows or should know of the action constituting the
basis for the [sanction]; or who is an officer or managing employee of such an entity.”51 OIG’s 2010
guidance explains that OIG will exercise a presumption in favor of exclusion under section (b)(15)
where there is evidence that an owner, officer, or managing employee52 knew or should have
known of the conduct leading to the exclusion or conviction of the entity, unless “significant factors”
weigh against exclusion. Therefore, OIG might exclude a certifying officer who submits inaccurate
payment reports and who should have known that such reports had errors or omissions. AMs must
also be aware of the possibility that FDA may use evidence of an incorrect or inaccurate reporting of
a research payment or other service related to product development to permissively debar officers.
Accordingly, executives and employees responsible for payment reporting must exercise due
diligence and establish explicit checks and balances at every level of data collection to reduce
potential individual liability. Additionally, given the tremendous burden Sunshine Act compliance
will have on compliance officers and staff, stakeholders may want to open a dialogue with OIG to
issue guidance or a special fraud alert, which could clarify OIG’s position on exclusion related to
Sunshine Act noncompliance.
VI.
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CONCLUSION

Shedding light on the interactions between AMs and CRs has several laudable goals. However,
these objectives must be carefully weighed against the tremendous value physician-industry
collaboration provides to the U.S. healthcare system and patients. Physicians should familiarize
themselves with the regulations to reflect on the propriety of their relationships with industry and
to determine whether a company really needs their expertise, the payment amount is reasonable,
and the company is not just paying them for their brand loyalty. Physicians must also evaluate the
size and frequency at which such interactions occur because government officials will be looking
at physicians engaged by AMs on a regular basis or for large sums of money. Physicians must
also be aware of how large and frequent payments may appear to their patients, colleagues and
institutions, and must be prepared to engage in a balanced conversation with patients that explains,
rather than defends, their relationships with industry. Lastly, physicians must realize that the Internal
Revenue Service may use published payments and relationships to evaluate any inconsistencies or
misreporting of taxes, and divorce attorneys may also use such payments.
To reduce the likelihood of inhibiting scientific discovery and collaboration, AMs and CRs must
proactively work together to structure their relationships to ensure compliance with the final
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Sunshine Act regulations and to minimize the risks associated with public disclosure of such
payments, including federal and state investigations and litigation, as well as private plaintiff and
consumer liability actions. Finally, CMS must work closely with all affected stakeholders to ensure
that the public is clearly aware that financial ties alone do not signify an inappropriate or illegal
relationship and beneficial relationships are not harmed.
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